NCT01787383已完成3 期
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment Area
研究概览
简要总结
The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate gel
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must provide informed consent
- •Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on face or scalp
- •Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on trunk or extremities
- •Subjects at least 18 years of age
- •Female subjects must be of either:
- •Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or,
- •Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to trial treatment, to rule out pregnancy.
- •Female subjects of childbearing potential must be willing to use effective contraception at trial entry and until completion.
排除标准
- •Location of the selected treatment areas:
- •on the periorbital skin
- •within 5 cm of an incompletely healed wound
- •within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)
- •Prior treatment with ingenol mebutate gel on face/scalp and on trunk/extremities
- •Lesions in the selected treatment areas that have:
- •atypical clinical appearance (and/or,
- •recalcitrant disease
- •History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication
- •Use of cosmetic or therapeutic products and procedures which could interfere with the assessments of the selected treatment areas
- •Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy during the course of the trial, as determined by the investigator's clinical judgment.
- •Anticipated need for hospitalisation or out-patient surgery during the first 15 days after the first trial medication application.
- •Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel
- •Presence of sunburn within the selected treatment areas
- •Current enrolment or participation in an investigational clinical trial within 30 days of entry into this trial
- •Subjects previously randomised in the trial
- •Female subjects who are breastfeeding
- •In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol
- •Prohibited Therapies and/or Medications within 2 weeks prior to Visit 1:
- •Cosmetic or therapeutic procedures within 2 cm of the selected treatment areas
- •Use of topical keratolytic therapeutic products within 2 cm of the selected treatment areas
- •Use of topical medicated creams, ointments, lotions, gels, foams or sprays including topical steroids : within 2 cm of the selected treatment areas; artificial tanners: within 5 cm of the selected treatment areas
- •Prohibited Therapies and/or Medications: within 4 weeks prior to Visit 1:
- •Treatment with immunomodulators, cytotoxic drugs or interferon/interferon inducers
- •Treatment with systemic medications that suppress the immune system
- •Treatment/therapy with ultraviolet light A (UVA) or ultraviolet light B (UVB)
- •Prohibited Therapies and/or Medications within 8 weeks prior to Visit 1:
- •Treatment with 5-fluorouracil (5-FU), imiquimod, topical diclofenac sodium, or photodynamic therapy within 2 cm of the selected treatment areas.
- •Prohibited Therapies and/or Medications within 6 months prior to Visit 1:
- •Use of systemic retinoids or biologic/monoclonal antibody therapies
研究组 & 干预措施
Ingenol mebutate gel 0.05 %
Active Comparator
干预措施: Ingenol mebutate gel 0.05 % (Drug)
Ingenol mebutate gel 0.05 %
Active Comparator
干预措施: Ingenol mebutate gel 0.015 % (Drug)
Ingenol mebutate gel 0.015 %
Active Comparator
干预措施: Ingenol mebutate gel 0.05 % (Drug)
Ingenol mebutate gel 0.015 %
Active Comparator
干预措施: Ingenol mebutate gel 0.015 % (Drug)
结局指标
主要结局
Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment Area
时间窗: 3 days after treatment of each selected treatment area
Composite Local Skin Reaction (LSR) score 3 days after treatment of each selected treatment area in both treatment groups (simultaneous or sequential). The composite LSR score (0 to 24), reflecting the sum of the individual LSR grades (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration, grade 0 to 4), was calculated for each selected treatment area at each visit.The composite LSR score ranges from 0 (best possible outcome) to 24 (worst possible outcome). Both affected areas were calculated together "Per Arm". Each subject could contribute with up to 2 values (1 for each treated area).
次要结局
- Complete Clearance of AKs in Each Separate Treatment Area 8 Weeks After Treatment(8 weeks after treatment)
- Partial Clearance of AKs in Each Separate Treatment Area 8 Weeks After Treatment(8 weeks after treatment)
- Percent Reduction in Number of AKs in Each Separate Treatment Area 8 Weeks After Treatment(8 weeks after treatment)
- Effectiveness Satisfaction Questionnaire for Medication (TSQM)(8 weeks)
- Side Effects TSQM(8 weeks)
- Global Satisfaction TSQM(8 weeks)
- Convenience TSQM(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)Rheumatoid ArthritisNCT00664521Merck KGaA, Darmstadt, Germany27
已完成
不适用
Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C InfectionHepatitis C InfectionNCT01771653Southern Illinois University37
进行中（未招募）
不适用
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen with Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas with Actinic Keratosis on Face/Scalp and Trunk/ExtremitiesActinic KeratosisMedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-002863-88-ESEO PHARMA A/S200
进行中（未招募）
不适用
A Simultaneous Treatment Regimen Compared to a Sequential TreatmentRegimen with Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas withActinic Keratosis on Face/Scalp and Trunk/ExtremitiesMedDRA version: 14.1Level: PTClassification code 10000614Term: Actinic keratosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersActinic KeratosisEUCTR2012-002863-88-ITEO PHARMA A/S200
已完成
3 期
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus RaltegravirHIV InfectionNCT00708162Gilead Sciences724